ArticleThe Journal of dermatology2025
Elevated Serum Immunoglobulin G1 Levels and Left Ventricular Diastolic Dysfunction in Anti-Centromere Antibody-Positive Patients With Lower Extremity Arterial Disease: A Cross-Sectional Study.
Article in The Journal of dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
This cross-sectional pilot study investigated the clinical characteristics of anti-centromere antibody (ACA)-positive patients with below-the-knee arterial disease. Sixteen ACA-positive patients (mean age 69 ± 10 years; 94% women) underwent contrast-enhanced computed tomography evaluation, with arterial damage scored using the Global Limb Anatomic Staging System. Lower extremity arterial disease (LEAD) was defined as a below-the-knee arterial score ≥ 1 or > 50% stenosis in above-the-knee lesions. Eight patients were categorized into the LEAD group (below-the-knee arterial damage score 12 ± 6). The LEAD group showed significantly higher serum IgG1 levels (1029 ± 484 vs. 531 ± 72 mg/dL, p < 0.001) and a higher prevalence of diastolic dysfunction (62% vs. 0%, p = 0.026) compared to the non-LEAD group. Patients with diastolic dysfunction had significantly higher serum IgG1 levels than those without (1190 ± 559 vs. 593 ± 139 mg/dL, p = 0.008). These findings suggest associations between elevated serum IgG1 levels, below-the-knee arterial disease, and left ventricular diastolic dysfunction in ACA-positive patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.